Connect to other sites within the UBM Medica Network
No benefit of axillary lymph node evaluation has been shown for women with DCIS, yet this lymph node analysis is still often performed in these patients. Image © Blamb / Shutterstock.com.
Drug Creates ‘Inhospitable’ Environment for Breast Cancer Progression
Early trial results suggest that a copper-depleting agent may create an inhospitable environment for tumor progression in patients with breast cancer.
Promising Results for Enzalutamide in Triple-Negative Breast Cancer
The prostate cancer drug enzalutamide has shown activity in women with advanced triple-negative breast cancer whose tumors express the androgen receptor.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
Cavity Shave Margins Help Decrease Morbidity in Breast Cancer
Performing a cavity shave margin in breast cancer patients undergoing partial mastectomy can reduce re-excision and positive margin rates after surgery.
Breast Cancer Family History Does Not Mean Poor Prognosis
A new study suggests that a family history of breast cancer does not result in a worse prognosis breast cancer prognosis.
3D Screening Can Detect More Breast Cancer Lesions
A Swedish study found that 3D tomosynthesis screening detected 40% more cases of breast cancer compared with traditional digital mammography.
Majority of Metaplastic Breast Cancers May Be Targetable
In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
Impact of ALTTO Results on Patients With HER2-Positive Breast Cancer
In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.